Navigation Links
Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017

Generic Erosion Will Reduce Sales of Schering-Plough's Temodar/Temodal, the Current Market Leader, According to a New Report from Decision Resources

WALTHAM, Mass., Dec. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the approval of agents to treat glioma, most notably Roche/Genentech/Chugai's Avastin, will drive market sales to more than double to more than $1.8 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Glioma finds that sales of Avastin, which is already used off-label to treat relapsed glioma and is in development for treating both relapsed and newly-diagnosed patients, will account for more than half of the total market in 2017. Sales of Schering-Plough's Temodar/Temodal, the current leading agent for glioma in both patient share and market share, will fall significantly from 2007 to 2017, owing to generic erosion.

According to the report, in addition to Avastin, the launches of Celldex Therapeutics/Pfizer's CDX-110 and Merck KGaA's cilengitide will also drive market growth. CDX-110 and cilengitide are being developed for use in newly diagnosed glioma patients and would each be used in combination with Temodar/Temodal. Additionally, overall sales for glioma therapies will be fueled by the launch of AstraZeneca's Recentin, which is in development for relapsed treatment.

"The treatment of glioma, especially the most malignant form--glioblastoma multiforme--is largely ineffective, and the prognosis for these patients is very poor," said Ramya Kollipara, Ph.D. analyst at Decision Resources. "Considerable opportunity remains in this market as currently-approved agents provide only modest improvements in patient outcomes, leaving a high level of unmet need."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources
    Christopher Comfort

    Decision Resources, Inc.
    Elizabeth Marshall

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Panel Says No to Avastin for Advanced Breast Cancer
2. Taxol with avastin produces noteworthy results
3. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
4. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
5. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
6. FDA OKs Avastin for Advanced Breast Cancer
7. Off-Label Avastin Use for Wet Macular Degeneration
8. Avastin Added to Chemo Helps Women With Advanced Cancer
9. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
10. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
11. Another Reason Not to Smoke While Pregnant: Birth Defects
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... While powdered ... results in wasted time. Fortunately, an inventor from Chesterfield, Va., has found an easy ... to keep the scoop used to measure powdered contents in a canister or other ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy Mitchell ... top ophthalmologist on Long Island’s east end. During the broadcast, entitled “Eyes: the Window ... treatment of glaucoma and cataracts, and how a visit with his grandmother to her ...
(Date:11/30/2015)... ... ... It’s inevitable that everyone will experience death in his or her lifetime. ... lives among us. It is your perspective, however, that determines how you view death ... T Sky understands that she may see death more frequently than most. As she ...
(Date:11/30/2015)... New York (PRWEB) , ... November 30, 2015 , ... ... Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex business decisions ... visit the booth will receive a free fee survey with 10 procedures customized by ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... strategic alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair ... polymers, TIGR® Matrix is a long-term resorbable surgical mesh intended to support and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 2014RestatedChange%Turnover ... , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance Administration ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , 2,917 ...
(Date:11/30/2015)... INDIANAPOLIS , Nov. 30, 2015  PTS Diagnostics, ... as CardioChek ® analyzers, A1CNow ® systems, ... of a family of patents that will propel the ... and Europe . The ... cameras, such as those on smartphones and tablets, and ...
(Date:11/30/2015)... , Nov. 30, 2015 Cumberland Pharmaceuticals (CPIX), today ... live at on December 3, 2015. TIME: ... TIME: 3:15p.m. ET LINK: --> ... --> ... where investors are invited to ask the company questions in ...
Breaking Medicine Technology: